Sentences with phrase «systems therapy at»

Not exact matches

Still, electroceutical therapies may still have many applications in the peripheral nervous system, such as bladder control or appetite suppression, says researcher Jose Carmena, a neuroscientist and electrical engineer at the University of California at Berkeley.

One setback for these therapies which use the body's immune system to fight cancers is that they are, at times, more effective in certain patient pools than others.

The injection will bankroll the continuing technical development of the firm's first LIGHT system and its installation at the Harley Street Proton Therapy Centre

Where there is reiteration instead of reversion, there may be need of therapy, a need for new possibilities to be introduced from someone outside and therefore relatively unaffected by the reiteration (at least initially) in order to free the system to find new solutions utilizing other approaches.

In Gestalt Therapy, the self is called «the system of contacts at any moment» (GT 235) and is a gestalt (as the dominant occasion is an actual occasion), though the theory does not emphasize this.The «self is spontaneous, middle in mode...» (GT 376).

The second category of systemic therapies aims at changing ongoing, natural systems such as marriages and families.

Wenger was not afraid to use tactical shock therapy after last month's humbling at Crystal Palace, tweaking his team into a 3 -4-3 system.

The full results haven't yet been published, but what has been revealed so far of this «antisense» therapy suggests we have overcome the biggest obstacle — how to deliver such therapies — at least in disorders that affect the nervous system.

Revving up the immune system to combat a wide variety of tumor types may take cancer therapy in a new direction, says Khaled Barakat, a computational scientist at the University of Alberta in Canada, who was not involved in the study.

We believe that they will also lead to the development of a whole new range of therapies for neurodegenerative diseases of the central nervous system,» explains corresponding author of the study Jihwan Song, professor and director of Neural Regeneration and Therapy Group at the CHA Stem Cell Institute of CHA University.

«Steep funding cuts for the federal health agencies are counterproductive at a time when innovative research is moving us closer to identifying solutions for rare diseases, new prevention strategies to protect Americans from deadly and costly conditions, advances in gene therapy, new technologies for understanding the brain, and treatments that harness the ability of our immune system to fight cancer.»

Treatments aimed at revving up the immune system's attack on the cancer may be the most promising approach to cancer therapy since combination chemotherapy.

«Our study reveals a new mechanism that could be harnessed for biological therapies for lupus and other autoimmune diseases, where the immune system mistakenly targets the body's own cells,» says senior study author Boris Reizis, PhD, professor of Pathology and Medicine at NYU Langone.

At the moment a lot of therapies are focused on the site of infection or injury itself but this data suggests that it's the signals that are being sent out from the gut that are impacting the whole immune system.

My cancer systems biology team at the University of California, Merced, is tackling diagnosis and treatment of therapy - resistant cancers by elucidating the network of changes within cells as a way to identify new drug targets and circumvent cancer resistance.

Dr. Cripe and his colleagues at The Ohio State University, the University of Pittsburgh School of Medicine and Cincinnati Children's Hospital Medical Center tested how well the oncolytic viral therapy — a cancer - killing form of the herpes simplex virus, called oHSV — infected and killed tumor cells in mice with and without a healthy immune system.

«Several groups are working on delivering genes using this system,» says Varavani Dwarki, a gene therapy researcher at Chiron Corp. in Emeryville, California.

«We agreed that whole - blood therapies and convalescent serum may be used to treat Ebola virus disease and that all efforts must be invested into helping affected countries use them safely,» Marie - Paule Kieny, assistant director general for health systems and innovation at WHO told reporters.

Enhancing such an interaction, perhaps in combination with other therapies that attack the virus at other stages of its life cycle, could give the immune system the opening it needs to overcome an infection.

The ability of these children to maintain an intact immune system in the face of ongoing viral replication and in the absence of antiretroviral therapy can provide us with new insights into hitherto unknown defense mechanisms, which could eventually benefit other HIV patients,» says Professor Oliver T. Keppler, Chair of Virology at the Pettenkofer Institute, and former head of the German Reference Center for Retroviruses in Frankfurt am Main.

Treatments such as behavioral therapies or continuous glucose - monitoring systems can prevent these events in many — but not all — people with this impaired awareness, leaving a substantial number of people at risk.

«The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical School.

The prospect of combining genomically targeted therapies with drugs that free the immune system to attack cancer suggests «we are finally poised to deliver curative therapies to cancer patients,» researchers at The University of Texas MD Anderson Cancer Center note in a review in the April 9 edition of Cell.

The answer to increasing the effectiveness of immune therapies, or perhaps at least to choosing which patients are most likely to benefit from immune therapies, may lie in understanding the ways viruses (and cancers themselves) have evolved to evade the immune system.

«The link between metabolism and cancer has been proposed or inferred to exist for a long time, but what is more scarce is evidence for a direct connection — genetic mutations in metabolic enzymes,» said senior author Ricardo C.T. Aguiar, M.D., Ph.D., associate professor of hematology - oncology in the School of Medicine and a faculty scientist with the Cancer Therapy & Research Center (CTRC) at the UT Health Science Center and the South Texas Veterans Health Care System, Audie L. Murphy Division.

«This camera has the potential to greatly enhance our understanding of very fast biological interactions and chemical processes that will allow us to build better models of complex, dynamical systems such as cellular respiration, or to help doctors better deliver and monitor light - based therapies,» says Richard Conroy, Ph.D., program director for Optical Imaging at NIBIB.

The bots might arrive at a clot, for example, and then using an internal power system, obliterate the clot with a precisely targeted drug or therapy.

They lie dormant and can not be eliminated by anti-retroviral therapy, nor by the weakened immune system, so that if treatment is stopped at any time, the virus starts to replicate and infect more cells again, while the immune system can not suppress this rebound of HIV infection.

«New way to unmask melanoma cells to the immune system: Lab studies show promise for a clinical trial aimed at improving current immune therapies.»

«Understanding how cancers suppress the immune system is the key to identifying more effective immuno - therapies,» said Brent Hanks, M.D., Ph.D., at Duke and senior author of the study.

«Unfortunately, there are no preventive therapies for any common disorder of the human nervous system — Alzheimer's, Parkinson's, schizophrenia, epilepsy — with the exception of blood pressure - lowering drugs to reduce the likelihood of stroke,» said study author James O. McNamara, M.D., professor of neurobiology at Duke Medicine.

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

So far, DARPA has released two calls for grant applications, with at least one more likely: The first, called SUBNETS (Systems - Based Neurotechnology for Emerging Therapies), asks researchers to develop novel, wireless devices, such as deep brain stimulators, that can cure neurological disorders such as posttraumatic stress (PTS), major depression, and chronic pain.

«With the development of effective treatments, the most limiting factor to treating acute stroke is infrastructure — we have to keep evolving our systems to get therapy to as many appropriate patients as possible,» says Ferdinand K. Hui, M.D., associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine.

The white paper recommends that practitioners follow relevant guidance documents and that deviation from consensus recommendations should be supported by clinical studies or pursued in the setting of a clinical trial approved by an institutional review board; that practitioners receive training in a new procedure before beginning its practice, that the training should include a practical, «hands - on» component and that all team members directly involved with the radiation therapy decisions should participate in at least five proctored cases before performing similar procedures independently; and that professional societies should accelerate the generation of new or updated guidance documents for the following disease sites and techniques: skin, central nervous system, gastrointestinal, lung or endobronchial and esophagus, and, while outside the charge of this panel, assess the need for updated guidance documents for accelerated partial breast irradiation using electronic brachytherapy.

They currently have a trial under way at the U-M Health System which tests a two - part gene therapy approach in patients with brain tumors called gliomas in an effort to get the immune system to attack the System which tests a two - part gene therapy approach in patients with brain tumors called gliomas in an effort to get the immune system to attack the system to attack the tumor.

Scientists at the Universitat Autònoma de Barcelona (UAB) and the Catalan Institute for Nanoscience and Nanotechnology (ICN2) have developed a nanoencapsulation system with a liposome coating in order to increase the efficacy of bacteriophages in oral phage therapy.

At the Cancer Institute of New Jersey, a team of physician - scientists, bioinformatics specialists, systems biologists, pathologists and a host of others meets weekly to discuss profiling results and determine therapy options.

The whole genome and RNA sequencing data were analyzed by a team of bioinformaticians and oncologists at the NYGC as well as a beta version of IBM Watson for Genomics, an automated system for prioritizing somatic variants and identifying potential therapies.

Geneva, Switzerland, 26 March 2014 — A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

An international research team led by Université de Montréal medical professor Christopher Rudd, director of research in immunology and cell therapy at Maisonneuve - Rosemont Hospital Research Centre, has identified a key new mechanism that regulates the ability of T - cells of the immune system to react against foreign antigens and cancer.

Other research at U-M is developing new options for treating brain cancer through immunotherapy — harnessing the immune system to attack cancer cells once an injection of a particular gene therapy is delivered into the brain tumor.

They encourage research aimed at translating laboratory discoveries about the brain and nervous system into diagnoses and therapies to improve human health.

The presentation, entitled «Ibudilast — Phosphodiesterase Type 4 Inhibitor — Bi-Modal Therapy with Riluzole in Early Cohort and Advanced Amyotrophic Lateral Sclerosis (ALS) Patients — Final Report and Future Directions «(Source) will be presented by principal investigator of the clinical study, Dr. Benjamin Rix Brooks, of the Carolinas HealthCare System's Neuromuscular / ALS - MDA Center at Carolinas HealthCare System Neurosciences Institute.

Her aim is to understand, at the molecular level, the mechanisms that control communication between the brain, immune system, and blood vessels — with the ultimate goal of designing new therapies that slow, stop, or reverse the progression of a wide range of neurological disorders, such as MS. Recently, Dr. Akassoglou's lab identified how microglia — a type of immune cell that acts as the brain's first line of defense — are activated when fibrinogen enters the brain or spinal cord.

Patients with severe combined immunodeficiency (SCID) show unprecedented immune system recovery after receiving gene therapy developed at St. Jude.

Included among the numerous recipients of Mr. Sanford's gifts, that total more than one billion dollars, are: the Edith Sanford Foundation for Breast Cancer that was created in 2012 by a gift of $ 100 million in honor of Mr. Sanford's mother who died of breast cancer when he was four years old; the Sioux Valley Hospitals and Health System, which renamed itself Sanford Health in 2007, in recognition of a $ 400 million gift; a $ 125 million gift in 2014 to establish Sanford Imagenetics, a program that will integrate genomic medicine into primary care for adults; the University of California San Diego which received a $ 100 million gift for the creation of the Sanford Stem Cell Clinical Center in 2013 to accelerate the translation of stem cell research discoveries by advancing clinical trials and patient therapies; the Burnham Institute for Medical Research that received a $ 50 million gift in 2010, and recognized its appreciation for both this and a 2008 gift of $ 20 million to the Sanford Center for Childhood Disease research at Burnham by then changing its name to Sanford Burnham Medical Research Institute; a $ 70 million gift to establish a particle physics laboratory named the Sanford Underground Research Facility; and the San Diego Consortium for Regenerative Medicine which received a gift of $ 30 million in 2008 and expressed its gratitude by renaming itself the Sanford Consortium for Regenerative Medicine.

And a subset of those may be treatable not with antidepressants but rather with therapy directed at the immune system.

2/12/2008 Gene Therapy Protocol at UCSD Activates Immune System in Patients with Leukemia A research team at the Rebecca and John Moores UCSD Cancer Center at University of California, San Diego (UCSD) reports that patients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies thTherapy Protocol at UCSD Activates Immune System in Patients with Leukemia A research team at the Rebecca and John Moores UCSD Cancer Center at University of California, San Diego (UCSD) reports that patients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies ththerapy protocol began making antibodies that r...

LA JOLLA, CA — Using a gene therapy delivery system developed in the laboratory of Inder Verma at the Salk Institute for Biological Studies, an international team of researchers successfully treated two...